Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study

Alice Gottlieb, Alan Menter, April Armstrong, Christopher Ocampo, Yihua Gu, Henrique D Teixeira
Journal of Drugs in Dermatology: JDD 2016 October 1, 15 (10): 1192-1196

BACKGROUND: Hidradenitis Suppurativa (HS), also known as acne inversa, is a painful, chronic, debilitating, inflammatory skin disease and has shown response to anti-TNF-α therapy. Efficacy and safety of the anti-TNF-α agent, adalimumab, was assessed in a post hoc analysis of women from the first 16 weeks of a phase 2 study of men and women with HS.

METHODS: Patients with moderate-to-severe HS in at least 2 body areas, unresponsive or intolerant to oral antibiotics for treatment of their HS, and with no previous anti-TNF-a or systemic non-biologic treatment, were randomized 1:1:1 to 40 mg adalimumab-weekly or every-other-week, or placebo. Efficacy was analyzed post hoc for women from the intent-to-treat population (ITT Population). Efficacy was analyzed for the primary endpoint Hidradenitis Suppurativa Physicians Global Response Clinical Response (HS-PGA Clinical Response), Hidradenitis Suppurativa Clinical Response (HiSCR, defined as a ≥50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count relative to baseline), and a pain endpoint, represented by 30% reduction measured by visual analog scale (VAS30).

RESULTS: At week 16, a higher percentage of women randomized to adalimumab-weekly vs. every-other-week or placebo achieved treatment response measured by HS-PGA (19.4% vs. 7.9% or 5.6%; P>.05), by HiSCR (51.6% vs. 24.2% or 27.6%; P>.05), and achieved VAS30 (50.0% vs. 34.3%; P>.05 or 21.2% P<.05; significant for adalimumab-weekly vs. placebo). Four women had serious adverse events (anemia, benign neoplasm, pneumonia, and suicide attempt). There were no fatalities. Women had a similarly acceptable safety profile as the overall study population.

CONCLUSION: In this subpopulation of women with moderate-to-severe HS, a greater proportion achieved reduction in HS severity and pain with adalimumab 40 mg weekly dosing compared with every-other-week or placebo. No new safety signals were identified. <br /><br /> <em>J Drugs Dermatol.</em> 2016;15(10):1192-1196.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"